Increased reflux burden on pre-transplant reflux testing independently predicts significant pulmonary function decline after lung transplantation

Table 2 Baseline demographics of cohort demonstrated no association with forced expiratory volume in 1 decline on time-to-event analysis

Characteristics	Univariate hazard ratio for pulmonary function decline (95%CI)	P value
Male sex	2.14 (0.67-6.87)	0.20
BMI	0.98 (0.87-1.09)	0.70
Age at transplant	1.00 (0.95-1.04)	0.85
White race	0.59 (0.08-4.59)	0.62
Pulmonary diagnosis
ILD	2.29 (0.71-7.39)	0.16
IPF	2.73 (0.94-7.89)	0.06
COPD	0	-
Other	0.91 (0.28-2.94)	0.87
Cardiac function, baseline
LVEF	0.19 (0-4512)	0.75
PaP (mm Hg)	1.00 (0.95-1.06)	0.85
PCWP (mm Hg)	1.00 (0.90-1.11)	0.98
PVR (dynes/cm5)	1.00 (0.99-1.00)	0.58
Pulmonary function, baseline
FVC	1.14 (0.62-2.11)	0.67
FVC, %-pred	0.30 (0.01-9.66)	0.49
FEV1	1.67 (0.84-3.32)	0.14
FEV1, %-pred	3.25 (0.24-43.9)	0.37
FEV1/FVC	6.21 (0.46-83.7)	0.17
Bilateral lung transplant	0.74 (0.25-2.16)	0.59
CMV mismatch	0.77 (0.21-2.76)	0.69
Increased risk donor	0.62 (0.08-4.84)	0.65
Post-transplant infection	1.40 (0.49-4.01)	0.53
Post-transplant PPI	1.57 (0.35-7.04)	0.55

Increased risk donors were those with hepatitis C infection. Post-transplant infection were those with infection detected on bronchoalveolar lavage prior to pulmonary decline.

CI: Confidence interval; BMI: Body mass index; IPF: Idiopathic pulmonary fibrosis; ILD: Interstitial lung fibrosis; COPD: Chronic obstructive pulmonary disease; CF: Cystic fibrosis; LVEF: Left ventricular ejection fraction; PaP: Pulmonary artery pressure; PCWP: Pulmonary capillary wedge pressure; PVR: Pulmonary vascular resistance; FVC: Forced vital capacity; %-pred: Percent predicted value; FEV1: Forced expiratory volume in 1 second; CMV: Cytomegalovirus; PPI: Proton pump inhibitor.